Formulation Development
Pfizer & BioNTech Reach Agreement to Supply the EU With 200 Million Doses of COVID-19 Vaccine
Pfizer and BioNTech SE recently announced they have reached an agreement with the European Commission to supply 200 million doses of their investigational….
Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion
Emisphere Technologies, Inc. recently announced it has entered into a definitive agreement with Novo Nordisk, whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for….
CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes
CymaBay Therapeutics, Inc. recently announced it will provide its proprietary investigational GPR119 agonist, MBX-2982, and will assist in regulatory filings for….
eGenesis Announces Research Collaboration With Leading Academic Medical Center
eGenesis recently announced the initiation of a research collaboration with Duke University School of Medicine. The collaboration will encompass evaluation of gene-edited pancreatic islet….
Calithera Biosciences Announces Expansion of Ongoing Clinical Trial
Calithera Biosciences, Inc. recently announced the expansion of the company’s ongoing clinical trial evaluating telaglenastat in combination with Pfizer’s CDK 4/6 inhibitor palbociclib….
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application
Biogen and Eisai, Co., Ltd. recently announced that the European Medicines Agency (EMA) has confirmed it has accepted for review, following a standard timetable, the…
Taysha Gene Therapies Bolsters Manufacturing Capacity Through Partnership
Taysha Gene Therapies Inc. and Catalent recently announced a partnership to support the development and manufacturing of Taysha’s gene therapies at Catalent’s Maryland-based gene therapy…
Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial
Rubius Therapeutics, Inc. recently announced that the first patient with acute myeloid leukemia (AML) has been dosed in its ongoing Phase 1/2 clinical trial of…
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation
Orchard Therapeutics recently announced the presentation of new clinical data at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting to be held virtually…
Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials for the Treatment of Parkinson’s Disease
Cerevel Therapeutics recently announced that the first participants have been dosed in all three of the clinical trials in their Phase 3 program evaluating tavapadon…
Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies
Aerogen recently announced details of a broad collaborative effort to support pharmaceutical companies from around the world as they work to develop COVID-19 vaccines and…
APPLY NOW ! - A Novel Approach for Incentivizing Drug Delivery Innovation
One of the most critical early steps in the development of novel drug delivery systems is to demonstrate convincing proof-of-concept. The dilemma is that while pharma companies can be interested in….
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company
Vedere Bio, Inc. recently announced it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and….
Apellis & Sobi Enter Collaboration for Global Co-Development & Ex-US Commercialization of Systemic Pegcetacoplan
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB recently announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted….
Catalent to Acquire Cell Therapy Manufacturing Facility From Bone Therapeutics
Catalent recently announced it had signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including…
XOMA Earns $25-Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study
XOMA Corporation recently announced NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 development stage, triggering a $25-million milestone payment…
Taconic Biosciences Launches Critical Model for COVID-19 Research
Taconic Biosciences recently announced immediate humanized ACE2 mouse model availability for COVID-19 research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter…
Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate
Orasis Pharmaceuticals recently announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the US, evaluating its novel eye drop candidate designed to…
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
Novavax, Inc. recently announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusion protein made…
miRagen Therapeutics Announces Acquisition of Viridian Therapeutics
miRagen Therapeutics, Inc. recently announced it has completed the acquisition of Viridian Therapeutics, Inc., a privately held biotechnology company focused on advancing new treatments for…